Dual Activation of GLP-1 and AMPK Pathways by a Multi-Botanical Formulation Improves Obesity and Metabolic

Anna Goc1, Waldemar Sumera1, Aleksandra Niedzwiecki1

  • 1Dr. Rath Research Institute BV, 5941 Optical Ct., San Jose, CA 95138, USA.

Nutrients
|July 15, 2026
PubMed
Abstract

Insights

A botanical formulation containing ginseng, curcumin, and other extracts was found to boost GLP-1 secretion and activate AMPK signaling. This natural compound reduced obesity markers in cell and animal models, showing potential for metabolic health management.

Area of Science:

  • Metabolic Health and Endocrinology
  • Nutraceutical Research
  • Obesity Pathophysiology

Background:

  • Obesity is a complex metabolic disorder linked to inflammation and disrupted energy regulation pathways.
  • Key pathways involved include glucagon-like peptide-1 (GLP-1) secretion and AMP-activated protein kinase (AMPK) signaling.

Purpose of the Study:

  • To investigate phytochemicals and botanical formulations for their ability to stimulate GLP-1 secretion.
  • To evaluate the potential of these compounds to activate AMPK signaling pathways.

Main Methods:

  • Screening of 14 phytochemicals and 6 combinations in human enteroendocrine cells for GLP-1 secretion and cytotoxicity.
  • Testing selected combinations in human adipocytes to assess effects on lipid accumulation and MCP-1 secretion.
  • In vivo studies using high-fat diet-induced obese mice to evaluate the efficacy of a promising botanical combination (Combination 4).

Main Results:

  • Combination 4, featuring ginseng, curcumin, white kidney bean, fenugreek, capsaicin, and bitter melon, significantly increased AMPK phosphorylation in vitro.
  • In obese mice, Combination 4 reduced body weight gain, white adipose tissue mass, and improved metabolic parameters.
  • The formulation increased GLP-1 levels and normalized GLP-1 receptor expression in adipose tissue, while restoring leptin and MCP-1 levels.

Conclusions:

  • The multi-component botanical formulation effectively modulates GLP-1 secretion, AMPK phosphorylation, lipid accumulation, and inflammation markers.
  • Preclinical data support this formulation as a non-toxic candidate for further investigation in metabolic management.
  • These findings provide a scientific basis for exploring botanical interventions in obesity and related metabolic disorders.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Global Regulatory Systems01:28

Global Regulatory Systems

Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...